Vinorelbine in elderly patients with inoperable nonsmall cell lung carcinoma: A phase II study

Cancer

Volumn 88, Issue 12, 2000, Pages 2677-2685

  Buccheri, Gianfranco ^a   Ferrigno, Domenico ^a  

^a S CROCE E CARLE HOSPITAL   (Italy)

Author keywords

Chemotherapy; Elderly patients; Nonsmall cell lung carcinoma (NSCLC); Phase II study; Vinorelbine

Indexed keywords

NAVELBINE;

AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DRUG EFFICACY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; FOLLOW UP; HUMAN; INJECTION PAIN; INOPERABLE CANCER; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL TIME; TUMOR REGRESSION; VOMITING;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINBLASTINE;

EID: 0034659879     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20000615)88:12<2677::AID-CNCR5>3.0.CO;2-B     Document Type: Article

References (37)

1. Haskell CM. Chemotherapy and survival of patients with non-small cell lung cancer: a contrary view. Chest 1991;99: 1325-6.
2. Douglas IS, White SR. Should non-small cell carcinoma of the lung be treated with chemotherapy? Con: Therapeutic empiricism - the case against chemotherapy in non-small cell lung cancer. Am J Respir Crit Care Med 1995;151:1288-91.
3. Souhami RL. Chemotherapy in non-small cell lung cancer: time to re-examine our attitudes. Thorax 1996;51:231-2.
4. Carney DN. Non-small cell lung cancer: slow but definite progress. Semin Oncol 1996;23(Suppl 16):5-6.
5. Buccheri G. Chemotherapy and survival in non-small cell lung cancer. The old 'vexata questio.' Chest 1991;99:1328-9.
6. Buccheri G. Chemotherapy and survival in non-small cell lung cancer: three years later. Chest 1994;106:990-2.
7. Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough. J Clin Oncol 1993;11:1866-72.
8. Souquet PJ, Chauvin F, Boissel JP, Cellerino R, Cormier Y, Ganz PA, et al. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet 1993;342:19-21.
9. Marino P, Pampallona S, Preatoni A, Cantoni A, Invernizzi F. Chemotherapy vs supportive care in advanced non-small-cell lung cancer: results of a meta-analysis of the literature. Chest 1994;106:861-5.
10. Alberti W, Anderson G, Bartolucci A, Bell D, Villalba JB, Brodin O, et al. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995;311: 899-909.
11. Gridelli C, Perrone F, Gallo C, De Marinis F, Ianniello G, Cigolari S, et al. Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study. Eur J Cancer 1997;33:392-7.
12. Veronesi A, Crivellari D, Magri MD, Cartei G, Mansutti M, Foladore S, et al. Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients. Eur J Cancer 1996;32A:1809-11.
13. Gridelli C, Perrone F, Gallo C, Rossi A, Scognamiglio F, Monfardini S, et al. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999;91:66-72.
14. Depierre A, Lemarie E, Dabouis G, Gamier G, Jacoulet P, Dalphin JC. A phase II study of Navelbine (vinorelbine) in the treatment of non-small cell lung cancer. Am J Clin Oncol 1991;14:115-9.
15. Berthaud P, Le Chevalier T, Ruffle P, Baldeyrou P, Arriagada R, Besson F, et al. Phase I-II study of vinorelhine (Navelbine) plus cisplatin in advanced non-small cell lung cancer. Eur J Cancer 1992;28A:1863-5.
16. Comella P, Frasci G, De Cataldis G, Panza N, Cioffi R, Curcio C, et al. Cisplatin/carboplatin + etoposide+vinorelbine in advanced non-small cell lung cancer: a multicentre randomised trial. Br J Cancer 1996;74:1805-11.
17. Le Chevalier T, Brisgand D, Douillard J-Y, Pujol J-L, Alberola V, Monnier A, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994;12:360-7.
18. Wozniak AJ, Crowley JJ, Balcerzak SP, Weiss GR, Spiridonidis CH, Baker LH, et al. Randomized trial comparing Cisplatin with Cisplatin plus Vinorelbine in the treatment of advanced non-small cell lung cancer: a Southwest Oncology Group Study. J Clin Oncol 1998;16:2459-65.
19. World Health Organization. International histological classification of tumours. Berlin: Springer-Verlag, 1991.
20. Zubrod CG, Scheiderman MA, Frei E, Brindley C, Gold LG, Shnider B, et al. Appraisal of methods for the study of chemotherapy in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J Chron Dis 1960;11:7-33.
21. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
22. Mountain CF. Revisions in the International System for Staging Lung Cancer [see comments]. Chest 1997;111:1710-7.
23. Tamburini M, Rosso S, Gamba A, Mencaglia E, De Conno F, Ventafridda V. A therapy impact questionnaire for quality-of-life assessment in advanced cancer research. Ann Oncol 1992;3:565-70.
24. Gehan FA. A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 1965;52:203-23.
25. Peto R, Pike MC, Armitage P. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977;35: 1-39.
26. Kaplan EL, Meier F. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;58:457-81.
27. Armitage P. Statistical methods in clinical research. Oxford: Blackwell Scientific Publications, 1971.
28. Buccheri G. Tumor markers: clinical meaning and use. In: Brambilla C, Brambilla E, editors. Lung tumors. New York: Marcel Dekker, Inc., 1999:435-52.
29. American Society of Clinical Oncology. Clinical practice guidelines for treatment of unresectable non-small-cell lung cancer. J Clin Oncol 1998;15:2996-3018.
30. National Cancer Institute. PDQ.Treatment.Healt Professionals. Non-small cell lung cancer. 1998. http://cancernet.nci.nih.gov/clinpdq/soa/Non-small_cell_lung_cancer_Physician. htlm.
31. Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Carboplatin, etoposide, and accelerated hyperfractionated radiotherapy for elderly patients with limited small cell lung cancer. A phase II study. Cancer 1998;82:836-41.
32. Nou E. Full chemotherapy in elderly patients with small cell bronchial carcinoma. Acta Oncol 1996;35:399-406.
33. Hickish TF, Smith IE, O'Brien MER, Ashley S, Middleton G. Clinical benefit from palliative chemotherapy in non-small cell lung cancer extends to the elderly and those with poor prognostic factors. Br J Cancer 1998;78:28-33.
34. Crawford JC, O'Rourke M, Schiller JH, Spiridonitis CH, Yanovich S, Ozer H, et al. Randomized trial of vinorelbine compared with fluorouracil plus leucoverin in patients with stage IV non-small-cell lung cancer. J Clin Oncol 1996;14: 2774-84.
35. Buccheri G, Ferrigno D. Efficacy of platinum-based regimes in non-small cell lung cancer. A negative report from the Cuneo Lung Cancer Study Group. Lung Cancer 1997;18:57-70.
36. Buccheri G, Ferrigno D, Rosso A, Vola F. Further evidence in favour of chemotherapy for inoperable non-small cell lung cancer. Lung Cancer 1990;6:87-98.
37. Buccheri G. Platinum-based chemotherapy for inoperable non-small cell lung cancer: a real therapeutic progress? Lung Cancer 1994;11:115-7.